ENO2 and androgen insensitivity syndrome: The serum NSE and S100-β levels in the control group were 13.35 [11.14–15.3] μg/L and 0.36 [0.21–0.66] μg/L, respectively, which were significantly higher than those in AIS patients with serum NSE levels of 17.50 [15.02–19.21] and S100-β levels of 0.72 [0.46–1.03] (P < 0.0001).